Takeda Pharmaceutical Company Limited American Depositary Receipt (TAK) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q4 25	—	-$32.7	—	—	$1.1T	—
Q3 25	—	$7.43	—	—	$7.5B	—
Q2 25	$87.5	$29.1	-66.8%	—	$7.7B	—
Q3 24	—	$33.8	—	—	$1.1T	—
Q2 24	—	-$15.5	—	—	$1T	—
Q1 24	$18.6	$28.8	+54.5%	—	$1.1T	—
Q4 23	—	$0.39	—	—	$956.2B	—
Q3 23	—	$0.59	—	—	$1.1T	—
Q2 23	$67.5	$20	-70.3%	—	$1T	—
Q1 23	$59.3	$34	-42.7%	—	$972.5B	—
Q4 22	—	$0.4	—	—	$873.3B	—
Q3 22	—	$0.52	—	—	$901.3B	—
Q2 22	$97	-$5.13	-105.3%	—	$844.8B	—
Q1 22	$95	$64	-32.6%	—	$949.6B	—
Q4 21	$88	$63.1	-28.3%	—	$770.3B	—
Q3 21	$105	$29.8	-71.6%	—	$836.8B	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY26	—	$60.9	—	—	$4.5T	—
FY25	—	$34.2	—	—	$4.6T	—
FY24	—	$46	—	—	$4.3T	—
FY23	—	$102.1	—	—	$4T

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	$1.7T	$1.8T	$2.1T	$3.3T	$3.2T	$3.6T	$4T	$4.3T	$4.6T	$4.5T
YoY change	-4.17%	+2.22%	+18.5%	+56.9%	-2.84%	+11.6%	+12.8%	+5.87%	+7.45%	-1.66%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	1.7T	1.8T	2.1T	3.3T	3.2T	3.6T	4T	4.3T	4.6T	4.5T
Cost of revenue	558.8B	495.9B	651.7B	1.1T	994.3B	1.1T	1.2T	1.4T	1.6T	1.6T
Gross profit	1.2T	1.3T	1.4T	2.2T	2.2T	2.5T	2.8T	2.8T	3T	2.9T
Gross margin	67.7%	72%	68.9%	66.9%	68.9%	69%	69.1%	66.5%	65.5%	65.1%
Research & development	312.3B	325.4B	368.3B	492.4B	455.8B	526.1B	633.3B	729.9B	730.2B	675.9B
Selling, general & administrative	619.1B	628.1B	717.6B	964.7B	875.7B	886.4B	997.3B	1.1T	1.1T	1.1T
Operating expenses	918.5B	965.5B	1.1T	1.5T	1.4T	1.4T	1.7T	1.9T	1.9T	1.8T
Operating income	98.1B	187B	192.3B	286.7B	417.6B	546B	554.9B	321B	486.1B	464.5B
Operating margin	5.66%	10.6%	9.17%	8.71%	13.1%	15.3%	13.8%	7.53%	10.6%	10.3%
Non-operating income, net	52.2B	37B	-3.7B	-200.8B	86.8B	-120B	-56.4B	-127.7B	-169.3B	-463B
Pretax income	143.3B	217.2B	127.6B	-60.8B	366.2B	302.6B	375.1B	52.8B	175.1B	-142.4B
Income tax	27.8B	30.5B	-7.5B	-105B	-9.9B	72.4B	58.1B	-91.4B	66.9B	9.8B
Net income	115.5B	186.7B	135.1B	44.3B	376.2B	230.2B	317B	144.2B	108.1B	-152.1B
Net margin	6.67%	10.5%	6.44%	1.35%	11.8%	6.45%	7.87%	3.38%	2.36%	-3.38%
EBITDA	268.6B	340.1B	383.5B	848.8B	970B	1.1T	1.2T	1T	1.2T	1.2T
EPS	73.6	119.7	70.3	14.2	120.4	73.6	102.1	46	34.2	60.9
Diluted EPS	73.1	118.8	69.9	14.1	119.5	72.9	101	45.6	33.6	59.8

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Revenue	1T	1.1T	1.1T	1.2T	7.7B	7.5B	1.1T	1.1T	1.1T	1.2T	1.1T	1.2T
Cost of revenue	343.6B	379.5B	382.5B	387B	2.6B	2.7B	382.1B	384.7B	380.1B	401.1B	405.7B	406.7B
Gross profit	699.5B	731.7B	668.4B	821B	5.1B	4.7B	671.3B	722B	732.7B	790.5B	688.8B	813.2B
Gross margin	67.1%	65.8%	63.6%	68%	66.5%	63.6%	63.7%	65.2%	65.8%	66.3%	62.9%	66.7%
Research & development	183.9B	187.4B	195.9B	168.5B	1.1B	1.1B	216B	143.9B	161.5B	175.2B	195.3B	167.4B
Selling, general & administrative	253B	267.5B	285.2B	270B	1.7B	1.8B	295.9B	255.9B	253.6B	282.8B	292B	286.5B
Operating expenses	508.6B	539.7B	426.4B	491.9B	2.6B	3.8B	399.7B	405.8B	458.6B	479.8B	491.9B	500.9B
Operating income	-49.3B	54.7B	96.8B	166.3B	1.8B	-146.4M	68.5B	184.6B	69B	168.8B	42.1B	201.4B
Operating margin	-4.73%	4.92%	9.21%	13.8%	23.3%	-1.96%	6.51%	16.7%	6.2%	14.2%	3.84%	16.5%
Non-operating income, net	2B	51.4B	-130.4B	-712M	-586.3M	570.2M	-166.1B	-536M	-2.1B	799M	-461.2B	538M
Pretax income	-96B	61.3B	-47.5B	136.6B	778.3M	172.2M	-107.3B	150.6B	28.2B	133.9B	-455B	162.7B
Income tax	-48B	-44.5B	-44.5B	41.3B	177.8M	16.8M	-4.2B	26.4B	39.9B	30.1B	-86.6B	49.5B
Net income	-48B	105.8B	-3B	95.3B	600.5M	155.4M	-103.1B	124.3B	-11.7B	103.7B	-368.4B	113.3B
Net margin	-4.6%	9.52%	-0.28%	7.89%	7.83%	2.08%	-9.79%	11.2%	-1.05%	8.7%	-33.7%	9.28%
EBITDA	202.3B	314.9B	86.1B	388.5B	2.5B	1.6B	73.3B	439.4B	316.5B	448.1B	-457B	337.5B
EPS	-15.3	—	—	30.4	—	—	—	39.7	—	—	—	35.8
Diluted EPS	-15.3	—	—	30	—	—	—	39.1	—	—	—	35.3

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Market cap	5.7T	5.9T	—	—	8.9T	6.9T	7.9T	—	47B	58.3B	60.4B
Enterprise value	6.5T	6.5T	—	—	12.5T	10.4T	11.8T	—	4.2T	4.3T	32.7B
Shares outstanding	242.5B	242.4B	298.4B	483.4B	484.8B	485.3B	481.7B	3.1B	3.2B	3.2B	3.2B

Valuation

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
P/E	49.6	31.7	—	—	23.5	30.2	25	—	0.43	—	42.2
P/S	3.31	3.34	—	—	2.77	1.95	1.97	—	0.01	0.01	0.01
P/B	2.94	2.93	—	—	1.71	1.22	1.25	—	0.01	0.01	1.24
EV/EBITDA	24.2	19.2	—	—	12.9	9.29	9.59	—	3.35	3.62	4.11
EV/Sales	3.75	3.69	—	—	3.9	2.92	2.92	—	0.91	0.96	1.11
Earnings yield	2.02%	3.16%	—	—	4.25%	3.31%	3.99%	—	230.3%	—	2.37%
FCF yield	2.61%	4.22%	—	—	8.75%	13.5%	4.33%	—	1.4K%	1.1K%	5.7%
PEG	—	—	—	—	—	—	—	—	—	—	-4.33

Profitability

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Gross margin	67.7%	72%	68.9%	66.9%	68.9%	69%	69.1%	66.5%	65.5%	65.1%	66.7%
Operating margin	5.66%	10.6%	9.17%	8.71%	13.1%	15.3%	13.8%	7.53%	10.6%	10.3%	16.4%
Net margin	6.67%	10.5%	6.44%	1.35%	11.8%	6.45%	7.87%	3.38%	2.36%	-3.38%	-3.54%
ROE	5.93%	9.25%	2.6%	0.94%	7.27%	4.05%	4.99%	1.98%	1.56%	-2.05%	-2.26%
ROA	2.66%	4.55%	0.98%	0.35%	2.91%	1.75%	2.27%	0.95%	0.76%	-0.98%	2.69%
ROIC	2.91%	6.12%	1.88%	3.13%	4.74%	4.54%	4.61%	2.76%	2.72%	3.98%	4.02%
Return on tangible assets	63.6%	960.5%	-3.22%	-1.25%	-12.6%	-7.03%	-7.62%	-3.38%	-2.95%	5.17%	5.64%

Financial health

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Current ratio	0.92	1.46	1.17	1.13	1.53	1.21	0.97	1.11	1.01	1.09	1.14
Quick ratio	0.76	1.17	0.81	0.79	1.1	0.81	0.57	0.58	0.52	0.6	0.62
Debt / equity	0.59	0.49	1.11	1.08	0.9	0.76	0.69	0.67	0.65	0.66	0.73
Debt / assets	0.26	0.24	0.42	0.4	0.36	0.33	0.31	0.32	0.32	0.31	0.32
Net debt / EBITDA	2.86	1.79	13.1	5.23	3.75	3.1	3.12	4.23	3.32	3.57	6.84
Interest coverage	20	22.6	3.65	0.59	3.8	3.47	4.21	1.44	2.28	0.04	-0.06
Effective tax rate	19.4%	14%	0%	0%	0%	23.9%	15.5%	0%	38.2%	0%	0%

Per share

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Revenue per share	7.14	7.31	7.03	6.81	6.6	7.35	8.36	1.4K	1.5K	1.4K	1.5K
EPS (basic)	73.6	119.7	70.3	14.2	120.4	73.6	102.1	46	34.2	60.9	60.9
EPS (diluted)	73.1	118.8	69.9	14.1	119.5	72.9	101	45.6	33.6	59.8	-0.33
Book value per share	8.04	8.32	17.4	9.78	10.7	11.7	13.2	2.3K	2.2K	2.4K	15.2
FCF per share	0.62	1.03	0.65	0.94	1.6	1.93	0.71	75.3	214.6	199	151.6
Cash per share	1.55	1.55	2.43	1.35	2.07	1.8	1.15	151.1	128.4	202.2	145.9
Capex per share	0.24	0.26	0.09	0.24	0.13	0.25	0.29	53.3	63.6	—	—

Capital allocation

Metric	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26	Current
Capex / revenue	3.41%	3.62%	1.29%	3.48%	2.02%	3.4%	3.47%	3.91%	4.38%	—	—
Capex / operating cash flow	18.3%	14.1%	5.7%	13.7%	4.89%	11.2%	11.9%	21.8%	18.1%	—	—
Payout ratio	122.7%	76%	105.8%	638%	75.3%	123.2%	88.1%	199.2%	279.7%	-205%	80%
Dividend yield	2.47%	2.4%	—	—	3.2%	4.08%	3.52%	—	644.2%	534.6%	3.67%

Yield

3.67%

trailing twelve months

Frequency

Semi-annual

Last dividend

$0.339

ex-dividend Mar 31, 2025

Payout ratio

80%

of earnings

Dividend growth

0 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Mar 31, 2025	$0.339
Sep 30, 2024	$0.326
Mar 27, 2024	$0.292
Sep 29, 2022	$0.3296
Mar 30, 2022	$0.3301
Sep 29, 2021	$0.3969
Mar 30, 2021	$0.4066
Sep 29, 2020	$0.4305

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Revenue	$1T	$1.1T	$1.1T	$1.2T	$7.7B	$7.5B	$1.1T	$1.1T	$1.1T	$1.2T	$1.1T	$1.2T
YoY change	+4.07%	+1.33%	+9.91%	+14.1%	-99.3%	-99.3%	+0.24%	-8.39%	+14.4K%	+15.9K%	+3.91%	+10.2%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Cash & short-term investments	376.1B	375.2B	725.4B	653.4B	1T	875B	553.7B	472.9B	405.6B	636.9B
Receivables	423.4B	369.7B	698.6B	715.2B	788.3B	710.3B	674.7B	718.7B	770.9B	977.4B
Inventory	226B	212.9B	919.7B	759.6B	753.9B	853.2B	986.5B	1.2T	1.2T	1.4T
Total current assets	1.3T	1.1T	3T	2.5T	2.7T	2.6T	2.4T	2.6T	2.5T	3.1T
Property, plant & equipment	—	-11.5B	374.9B	314.4B	320.5B	294.2B	291.1B	310.7B	296.3B	284.6B
Goodwill & intangibles	4.2T	4.1T	18T	16.4T	15.9T	16.5T	18.1T	19.4T	17.9T	18.5T
Total assets	4.3T	4.1T	13.8T	12.8T	12.9T	13.2T	14T	15.1T	14.2T	15.5T
Accounts payable	240.6B	133.7B	212.3B	211.6B	232.1B	295.9B	307.5B	320B	308.4B	324.4B
Short-term debt	545B	18M	984.9B	586.8B	22.2B	204B	339.6B	367.3B	548.9B	512.2B
Total current liabilities	1.4T	737.5B	2.6T	2.2T	1.8T	2.1T	2.5T	2.3T	2.5T	2.8T
Long-term debt	599.9B	985.6B	4.8T	4.5T	4.6T	4.1T	4T	4.5T	4T	4.4T
Total liabilities	2.4T	2.1T	8.6T	8.1T	7.7T	7.5T	7.6T	7.8T	7.3T	8.1T
Shareholders' equity	1.9T	2T	5.2T	4.7T	5.2T	5.7T	6.4T	7.3T	6.9T	7.4T
Total debt	1.1T	985.7B	5.8T	5.1T	4.6T	4.3T	4.4T	4.8T	4.5T	4.9T
Net debt	825.4B	691.1B	5T	4.5T	3.7T	3.5T	3.8T	4.4T	4.1T	4.3T

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Cash & short-term investments	333.8B	317.4B	472.9B	857.7B	5.9B	3.4B	405.6B	419.2B	739.7B	761.9B	636.9B	527.6B
Receivables	755.3B	716.2B	718.7B	755.4B	4.6B	4.6B	770.9B	665.6B	689B	736.5B	977.4B	930.4B
Inventory	1.2T	1.2T	1.2T	1.3T	7.9B	8.1B	1.2T	1.2T	1.3T	1.4T	1.4T	1.4T
Total current assets	2.5T	2.4T	2.6T	3.1T	19.9B	18B	2.5T	2.5T	2.9T	3.1T	3.1T	3.2T
Property, plant & equipment	—	—	310.7B	—	—	—	296.3B	—	—	—	284.6B	—
Goodwill & intangibles	19.4T	18.4T	19.4T	20.2T	116.5B	123.6B	17.9T	17.4T	17.5T	18.5T	18.5T	18.6T
Total assets	14.9T	14.2T	15.1T	16.2T	95B	98.5B	14.2T	14T	14.5T	15.4T	15.5T	15.7T
Accounts payable	421.1B	483.7B	320B	468.9B	2.7B	3B	308.4B	421.3B	439B	467.6B	324.4B	446.8B
Short-term debt	274.8B	370.3B	367.3B	438.7B	4.1B	883.4M	548.9B	371.1B	293.9B	583.1B	512.2B	520B
Total current liabilities	2.4T	2.3T	2.3T	2.5T	15.6B	13.7B	2.5T	2.2T	2.1T	2.6T	2.8T	2.8T
Long-term debt	4.4T	4.3T	4.5T	5T	28.9B	30.7B	4T	4.1T	4.4T	4.3T	4.4T	4.4T
Total liabilities	7.8T	7.5T	7.8T	8.4T	49.9B	50.1B	7.3T	7.1T	7.3T	7.8T	8.1T	8.1T
Shareholders' equity	7.1T	6.7T	7.3T	7.8T	45.1B	48.4B	6.9T	6.9T	7.1T	7.6T	7.4T	7.6T
Total debt	4.7T	4.7T	4.8T	5.5T	32.9B	31.6B	4.5T	4.5T	4.6T	4.9T	4.9T	4.9T
Net debt	4.4T	4.4T	4.4T	4.7T	27.3B	28.3B	4.1T	4.2T	4T	4.2T	4.3T	4.5T

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Net income	115.5B	186.7B	135.1B	44.3B	376.2B	230.2B	317B	144.2B	108.1B	-152.1B
Depreciation & amortization	171.4B	182.1B	247.7B	583.6B	559.7B	583.2B	664.4B	728B	761.4B	721.1B
Stock-based compensation	15.4B	18.6B	20.1B	29.1B	37.7B	43.4B	60.7B	70.9B	72.9B	72.8B
Change in working capital	-12.9B	13.4B	80.4B	131.8B	239.2B	-26.6B	59.5B	-246.1B	-52.3B	203.1B
Operating cash flow	322.1B	455.1B	472.9B	836.3B	1.3T	1.1T	1.2T	765.8B	1.1T	1T
Capital expenditure	-59B	-64B	-27B	-114.5B	-64.8B	-121.4B	-139.7B	-166.8B	-200.7B	—
Investing cash flow	-611B	-42.2B	-2.8T	369.9B	517.3B	-141.7B	-122.7B	-182.9B	-206.5B	20.4B
Dividends paid	-141.7B	-141.9B	-143B	-282.6B	-283.4B	-283.7B	-279.4B	-287.2B	-302.5B	-311.9B
Share repurchases	-23.1B	-18.8B	-1.2B	-3.7B	-2.1B	-77.5B	-26.9B	-2.3B	-51.9B	-51.6B
Financing cash flow	296.9B	-317.9B	3T	-1.2T	-981B	-962.1B	-600.6B	-254B	-638.4B	-717.2B
Net change in cash	8B	95B	665.7B	-23B	859.7B	-16.9B	454.4B	328.8B	265.5B	344.6B
Free cash flow	149.3B	249.6B	194.4B	452B	774.5B	937.1B	343.5B	235.6B	677.6B	626.8B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26	Q1 27
Net income	-48B	105.8B	-3B	95.3B	600.5M	155.4M	-103.1B	124.3B	-11.7B	103.7B	-368.4B	—
Depreciation & amortization	182.7B	187.1B	186.7B	192.2B	1.3B	1.2B	189.8B	181.6B	185B	190.6B	163.9B	—
Stock-based compensation	18.5B	18.7B	18.2B	15.4B	140.5M	119.3M	17.6B	16.5B	18.7B	17.8B	19.7B	—
Change in working capital	16.6B	-236.3B	89.9B	-42.7B	-464.1M	450.8M	-7.5B	-5.9B	5.4B	-42.6B	246.2B	—
Operating cash flow	163.8B	102.7B	328.1B	220.7B	2.1B	2.5B	196.3B	289.9B	378.2B	373.3B	74.5B	127.6M
Capital expenditure	-29.5B	-46.8B	-44.5B	-57.4B	-322.4M	-294M	-48.8B	-41.5B	—	—	—	—
Investing cash flow	-31.2B	-48.8B	-57.3B	-80.9B	-241.4M	-707.6M	19.9B	-11.1B	1.5B	-12.7B	1.2B	—
Dividends paid	-9.1B	-138.3B	-9.1B	-138.1B	-60M	-948.5M	-9.7B	-145.3B	-8.8B	-149B	-8.8B	—
Share repurchases	0	0	0	-1.9B	0	0	-50B	-51.6B	0	0	0	—
Financing cash flow	-110.8B	-68.8B	-36.5B	331.8B	-542.5M	-4B	-266.9B	-244.2B	69.7B	-162.7B	-380B	—
Net change in cash	21.9B	-14.9B	234.3B	471.7B	1.3B	-2.3B	-50.8B	34.5B	449.4B	197.9B	-304.3B	127.6M
Free cash flow	128.9B	69.3B	214.3B	32.5B	1.2B	2.1B	129.4B	140.4B	325.4B	150.9B	10.1B	127.6M

Takeda Pharmaceutical Company Limited American Depositary Receipt Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement